

AACR Special Conference in Cancer Research
RAS ONCOGENESIS AND THERAPEUTICS
March 5-8, 2026 | Los Angeles, CA

AACR American Association for Cancer Research

PROFERRED TALKS

PR001 B045 **Targeting S6K2 overcomes resistance to RAS inhibition in NRAS-mutant melanoma**, Jessie Villanueva, The Wistar Institute, Philadelphia, United States

PR002 A049 **Identification of a RAS-GTP Threshold for Malignant Transformation**, Sophie Krahnke, Frederick National Laboratory, Frederick, MD, United States

PR003 A029 **MEK1/2 degraders uncover kinase-independent role of MEK1/2 in CRAF stabilization and maturation,** James Duncan, Fox Chase Cancer Center, Philadelphia, PA, United States

PR004 A026 **Dissecting the critical ERK functions that support KRAS-driven pancreatic cancer,** Jennifer Klomp, Michigan State University, Grand Rapids, MI, United States

PR005 A044 **KRAS amplification as de novo oncogenic alteration and therapeutic target in human cancers**, Mark Awad, Memorial Sloan Kettering Cancer Center, New York, NY, United States

PR006 A045 **Comprehensive structure-function analysis reveals gain- and loss-of-function mechanisms impacting oncogenic KRAS activity**, Jason Kwon, Dana-Farber Cancer Institute, Boston, United States

PR007 B007 **Anti-tumor efficacy of the selective oral KRAS G12D dual ON/OFF inhibitor VS-7375 as a single agent and in combination with targeted agents**, Jonathan Pachter, Verastem Oncology, Needham, MA, United States

PR008 B004 **Preclinical activity of an orally bioavailable PROTAC pan-KRAS degrader versus inhibitors in mutant KRAS models**, Andrea Lopez-Arroyo, Arvinas Operations, Inc., New Haven, CT, United States

PR009 A007 **The RAS(ON) multi-selective inhibitor, daraxonrasib (RMC-6236), induces Receptor Tyrosine Kinase (RTK) cell surface expression on pancreatic cancer cells, providing rationale for combinations with RTK targeting agents**, Ida Aronchik, Revolution Medicines, Redwood City, CA, United States

PR010 A008 **ERK hyperactivation-induced lethality as a therapeutic strategy in RAS-driven tumors**, Alexa Cannon, Novartis Biomedical Research, Cambridge, MA, United States

PR011 A032 **KRAS amplification creates a targetable pMHC antigen for T cell engager therapy to overcome KRAS inhibitor resistance**, Lauren Stopfer, Aethon Therapeutics, New York City, NY, United States

PR012 A033 Kras **G12C and G12D driven lung cancers differ in oncogenic potency, immunogenicity, and relapse following Kras inhibition**, Esra Akbay, University of Texas Southwestern Medical Center, Dallas, TX, United States

PR013 B011 **Dynamic kinome reprogramming and metabolic rewiring drive adaptive resistance to RAS inhibition in pancreatic cancer**, Clint Stalnecker, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States

PR014 B012 **A PP2A molecular glue overcomes RAS/MAPK inhibitor resistance in KRAS-mutant non–small cell lung cancer**, Goutham Narla, The University of Michigan, Ann Arbor, MI, United States

PR015 B044 **Silent KRAS mutations confer altered sensitivity to targeted KRAS inhibition, Andrew Waters**, University of Cincinnati, Cincinnati, OH, United States

PR016 B048 **De novo design of Ras isoform selective binders**, Jason Zhang, UCLA, Los Angeles, CA, United States



AACR Special Conference in Cancer Research
RAS ONCOGENESIS AND THERAPEUTICS
March 5-8, 2026 | Los Angeles, CA

AACR American Association for Cancer Research

POSTER SESSION A
Friday, March 6, 2026

A001 **Uncovering the role of IMP2 in RAS signaling and colorectal cancer progression**. Jessica Das. CUNY Graduate Center, New York, NY, United States.

A002 **KRAS inhibitors as sensitizing agents in treatment-refractory rectal cancer**. Chao Wu. Department of Colon & Rectal Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

A003 **Enhancing the efficacy of KRAS-targeted therapy in colorectal cancer via Aurora kinase A inhibition**. Zhaojin Liu. University of Southern California, Los Angeles, CA, United States.

A004 **Experimental and Computational Validation of Alcea rosea Compounds in Blocking Colorectal Cancer Progression**. Ruhban Parry. University of Kashmir, Srinagar, 190003, India.

A005 **D3S-002: A Purposefully Designed ERK1/2 Inhibitor Achieving Low-Dose, Pulsatile Target Inhibition for Combination with D3S-001, a New-Generation KRAS G12C Inhibitor**. Jing Zhang. D3 Bio, Inc., Shanghai, Taiwan (Greater China).

A006 **Synergistic co-targeting of KRAS G12V and pan-TEAD by an EGFR-directed, inverted chimeric RNAi molecule**. Chad Pecot. University of North Carolina - Lineberger Cancer Center, Chapel Hill, NC, United States.

B045 **Targeting S6K2 overcomes resistance to RAS inhibition in NRAS-mutant melanoma**. Jessie Villanueva. The Wistar Institute, Philadelphia, United States.

A049 **Identification of a RAS-GTP Threshold for Malignant Transformation**. Sophie Krahnke. Frederick National Laboratory, Frederick, MD, United States.

A009 **Synergistically overcoming KRAS-driven radioresistance and immune evasion in PDAC with alpha particle radiotherapy and anti-CTLA-4**. Marco Reis. UT MD Anderson and Rice University, Houston, TX, United States.

A010 **Advancing new rational drug combinations to treat mutant KRAS-driven pancreatic adenocarcinoma**. Brajendra Tripathi. National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.

A011 **Decoding the codons: Uncovering KRAS mutant isoform-specific vulnerabilities in non-small cell lung cancer**. Will McDaid. University of Manchester, MANCHESTER, United Kingdom.

A012 **Combined AXL and KRAS inhibition synergize and drive immune recruitment in KRAS-mutant NSCLC**. Fredrik Thege. The Ohio State University Comprehensive Cancer Center, Columbus, OH, United States.

A013 **Targeted therapy-induced chromosomal instability dictates mitotic dependency on Aurora Kinase A**. Chendi Li. Massachusetts General Hospital/ Harvard Medical School, Boston, MA, United States.

A014 **Mapping the genetic landscape of KRAS mutant cancer cells using combinatorial CRISPR screens.** Rand Arafeh. Dana Farber Cancer Institute, Harvard Medical School & Broad Institute of MIT and Harvard, Boston, MA, United States.

A015 **AB801, a potent and selective clinical-stage AXL inhibitor, enhances the anti-tumor efficacy and duration of response of KRAS inhibitors**. Ester Fernandez-Salas. Arcus Biosciences, Hayward, CA, United States.

A016 **GAP mimetics display synergy with K-Ras Switch-II inhibition**. Patrick Pfaff. Department of Cellular and Molecular Pharmacology and Howard Hughes Medical Institute, University of California, San Francisco (UCSF), San Francisco, CA, United States.

A017 **RAS inhibition and cytotoxic chemotherapy target complementary cell states in pancreatic cancer**. Kenneth Olive. Columbia University Irving Medical Center, New York, NY, United States.

A018 **Functional chemo-genomic screening identifies novel combination therapies to treat RAS-driven multiple myeloma**. Omar S. Al-Odat. NCI, Bethesda, MD, United States.

A019 **Enhancing RAS therapies by targeting PIKfyve in pancreatic cancer**. Caleb Cheng. University of Michigan, Ann Arbor, MI, United States.

A020 **Applying a functional precision medicine platform, Optim.AI™, to identify novel KRAS inhibitor-based combinations in pancreatic cancer**. Edward Chow. KYAN Technologies Pte Ltd, Singapore, Singapore.

A021 **Enhancing therapeutic efficacy of RAS-targeted cancer therapy via co-targeting DNA topoisomerase II**. Zhen Chen. Winship Cancer Institute of Emory University, Atlanta, GA, United States.

A022 **Combination benefit of treatment with focal adhesion kinase inhibitor narmafotinib and KRAS inhibitors**. Christopher Burns. Amplia Therapeutics, Melbourne, VIC, Australia.

A023 **Combined RAS and ICB inhibition targets NF-κB–driven immune evasion in chemoresistant pancreatic cancer**. Kevin Christian Gulay. University of California San Diego, San Diego, CA, United States.

A024 **Characterization of rutin binding to HRAS and MAPK3 and its clinical prognostic relevance in lung cancer: Using in silico and clinical prognostic experimental design**. Dr. Hossam Kamli. King Khalid University, Abha, Saudi Arabia.

A025 **Unveiling Synergistic Potential of VHL and KEAP1-based PROTACs for Targeted Protein Degradation**. Sehbanul Islam. University of Pennsylvania, Philadelphia, PA, United States.

A029 **MEK1/2 degraders uncover kinase-independent role of MEK1/2 in CRAF stabilization and maturation**. James Duncan. Fox Chase Cancer Center, Philadelphia, PA, United States.

A027 **Molecular dynamics driving phenotypic divergence among KRAS mutants in pancreatic tumorigenesis**. David Falvo. Weill Cornell Medicine, New York, NY, United States.

A028 **Non-genetic resistance to multi-selective RAS(ON) inhibitors in NRAS-mutant melanoma**. Hee Won Yang. Columbia University, New York, NY, United States.

A026 **Dissecting the critical ERK functions that support KRAS-driven pancreatic cancer**. Jennifer Klomp. Michigan State University, Grand Rapids, MI, United States.

A030 **Branched Actin-driven Cell Membrane Protrusions Regulate Oncogenic KRAS Molecular Signaling**. Gabriel Muhire Gihana. UT Southwestern Medical Center, Dallas, TX, United States.

A031 **A metabolic weak spot: GJB3–SLC7A11 Synthetic lethality in colon cancer**. Disha Acharya. Indian Institute of Technology, Dharwad, Chikkamalligwad, Dharwad, India.

A044 **KRAS amplification as de novo oncogenic alteration and therapeutic target in human cancers**. Mark Awad. Memorial Sloan Kettering Cancer Center, New York, NY, United States.

A045 **Comprehensive structure-function analysis reveals gain- and loss-of-function mechanisms impacting oncogenic KRAS activity**. Jason Kwon. Dana-Farber Cancer Institute, Boston, United States.

A034 **Targeting phosphodiesterase 10A by ADT-030 normalizes the tumor immune microenvironment by inhibiting RAS-MAPK signaling in both cancer cells and myeloid-derived suppressor cells**. Gang Zhou. Augusta University, Augusta, GA, United States.

A035 **TCR-T cell therapy targeting mutant KRAS in pancreatic cancer using a humanized co-culture and mouse model system**. Georg Hilfenhaus. Charité-Universitätsmedizin Berlin, Berlin, Germany.

A036 **Developing the next generation of T cell engager (TCE): Combining high-throughput immunoassays with generative AI to develop TCEs toward multiple RAS mutations**. Dubravka Pezic. Synteny Biotechnology, London, United Kingdom.

A037 **Oncogenic KRAS signaling reversibly suppresses immunotherapy responses in non-small cell lung cancer**. Drithi Patel. Thomas Jefferson University, Philadelphia, PA, United States.

A038 **Targeting RAS in gynecologic cancers**. Elizabeth Stover. Dana-Farber Cancer Institute, Boston, MA, United States.

A039 **Towards the discovery of a panKRAS binder via the use of antibody derivatives**. Davide Cardella. The Institute of Cancer Research, Sutton, United Kingdom.



A040 **Remarkable in vivo responses to Ras targeting drug Daraxonrasib in a chemotherapy-resistant MMTV-Kras G12D syngeneic mammary tumor model**. Mehrnoosh Arabi. Tulane School of Medicine, New Orleans, LA, United States.

A041 **Genetic landscape of intracholecystic papillary neoplasms (ICPNs) of the gallbladder - STK11 as a characteristic driver gene for ICPNs-**. Satomi Saito. Department of Investigative Pathology, Tohoku University, Sendai, Japan.

A042 **Clinicopathological and molecular profiling of pancreatic adenocarcinoma: The Moroccan experience**. Fatima El Agy. 1. Laboratory of Biomedical and Translational Research, Faculty of Medicine, Pharmacy, and Dentistry of Fez, Sidi Mohamed Ben Abdellah University, Fez, Morocco, FEZ, Morocco.

A043 **Phosphorylation Protects Oncogenic RAS from LZTR1-Mediated Degradation**. Lin Zhang. NIH, Bethesda, MD, United States.

B007 **Anti-tumor efficacy of the selective oral KRAS G12D dual ON/OFF inhibitor VS-7375 as a single agent and in combination with targeted agents**. Jonathan Pachter. Verastem Oncology, Needham, MA, United States.

B004 **Preclinical activity of an orally bioavailable PROTAC pan-KRAS degrader versus inhibitors in mutant KRAS models**. Andrea López-Arroyo. Arvinas Operations, Inc., New Haven, CT, United States.

A046 **Discovery and characterization of a novel cryptic pocket in KRAS**. Michel Maira. Novartis Biomedical Research Oncology, Basel, Switzerland.

A047 **KRAS G12C and G12D mutants exhibit distinct conformational flexibility in the helix 3–switch 2 pocket that drives differential protein function**. ALOK SHARMA. NCI RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., FREDERICK, MD, United States.

A048 **Structure of SHOC2-KRAS-PP1C complex reveals RAS isoform-specific determinants and insights into targeting complex assembly by RAS inhibitors**. Jacob Potter. Frederick National Laboratory for Cancer Research, Frederick, MD, United States.

A007 **The RAS(ON) multi-selective inhibitor, daraxonrasib (RMC-6236), induces Receptor Tyrosine Kinase (RTK) cell surface expression on pancreatic cancer cells, providing rationale for combinations with RTK targeting agents**. Ida Aronchik. Revolution Medicines, Redwood City, CA, United States.

A050 **Mutant allele copy number gains define distinct molecular subtypes of oncogene-driven cancers and are associated with response to allele-specific KRAS G12C inhibitor sotorasib in NSCLC**. Maria Perry. Memorial Sloan Kettering Cancer Center, New York, NY, United States.



A051 **Recurrent RRAS and RRAS2 mutations in lung cancer define actionable oncogenic drivers with therapeutic susceptibility to pan-RAS inhibition**. Alexander Pfeil. Memorial Sloan Kettering Cancer Center, Chapel Hill, NC, United States.

A052 **ADT-030: A novel PDE10 inhibitor with robust and durable antitumor activity and the capacity to overcome resistance common to RAS inhibitors through dual blockade of RAS and β-catenin signaling**. Gary Piazza. Auburn University, Auburn, AL, United States.



AACR Special Conference in Cancer Research
RAS ONCOGENESIS AND THERAPEUTICS
March 5-8, 2026 | Los Angeles, CA

AACR American Association for Cancer Research

POSTER SESSION B
Saturday, March 7, 2026

B001 **eIF2B Selectively Anchors and Activates Mutant KRAS4B**. Hyungdong Kim. Lady Davis Institute for Medical Research, Sir Mortimer B. Davis Jewish General Hospital, Montreal, Quebec, H3T 1E2, Canada / Graduate Program in Clinical and Translational Research, Faculty of Medicine, McGill University, Montreal, Quebec, H4A 3J1, Canad, Montreal, QC, Canada.

B002 **Structural and functional analysis of the resistance mechanisms of KRAS-G12C secondary mutations to switch-II pocket inhibitors**. Matthew Whitley. Frederick National Laboratory for Cancer Research, Frederick, MD, United States.

B003 **Pan-Cancer Systematic Meta-Analysis of RAS Oncogene Mutational Landscapes and Therapeutic Vulnerabilities**. Shivi Kumar. University of Pennsylvania, Philadelphia, TX, United States.

A008 **ERK hyperactivation-induced lethality as a therapeutic strategy in RAS-driven tumors**. Alexa Cannon. Novartis Biomedical Research, Cambridge, MA, United States.

B005 **Noncovalent Pan-KRAS inhibitors: Broad-spectrum targeting of KRAS mutations in cancer**. Greg Jones. Pfizer, San Diego, CA, United States.

B006 **Screening a disulfide library against engineered cysteine RAS mutants reveals cryptic binding pockets**. Trent Balius. Frederick National Laboratory for Cancer Research, Frederick, MD, United States.

A032 **KRAS amplification creates a targetable pMHC antigen for T cell engager therapy to overcome KRAS inhibitor resistance**. Lauren Stopfer. Aethon Therapeutics, New York City, NY, United States.

B008 **Pharmacokinetics of daraxonrasib (RMC-6236): transporter and enzyme impact on a first-in-class pan-RAS molecular glue**. Davinia Arguedas. Netherlands Cancer Institute (NKI), Amsterdam, Netherlands.

B010 **Mutational landscape of RTK–RAS signaling pathway in acute myeloid leukemia: Insights from whole exome sequencing**. HARSH GOEL. ALL INDIA INSTITUTE OF MEDICAL SCIENCES, NEW DELHI, India.

A033 **Kras G12C and G12D driven lung cancers differ in oncogenic potency, immunogenicity, and relapse following Kras inhibition**. Esra Akbay. University of Texas Southwestern Medical Center, Dallas, TX, United States.

B011 **Dynamic kinome reprogramming and metabolic rewiring drive adaptive resistance to RAS inhibition in pancreatic cancer**. Clint Stalnecker. University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.

B013 **Reversing the ferroptosis-resistant phenotype of KEAP1 -mutant lung adenocarcinoma through glutaminase 1 inhibition enhances the efficacy of KRAS inhibitors**. Amirali Karimi. The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

B014 **A mechanistically distinct pan-RAS inhibitor, ADT-007, with robust antitumor activity evades resistance common to mutant-specific and pan-RAS Inhibitors**. Gary Piazza. Auburn University, Auburn, AL, United States.

B015 **Leveraging patient-derived organoids and matched 2D models to elucidate resistance mechanisms to KRAS inhibition in pancreatic cancer**. Nicolas Lecomte. David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York City, NY, United States.

B016 **hSSB2 Activators as a Dual Therapeutic Strategy for Overcoming RAS/MAPK Inhibitor Resistance While Protecting Normal Epithelia in Aggressive Cancers**. Andrew Norris. BCN Biosciences, Pasadena, CA, United States.

B017 **Mechanisms regulating resistance to KRAS inhibitors driven by ΔNp63 in lung adenocarcinoma**. Santanu Adhikary. H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States.

B018 **ZNF384 Orchestrates Cell-State Reprogramming and Kinome Remodeling in KRAS G12C Inhibitor Resistance**. Chendi Li. Massachusetts General Hospital Cancer Center/Harvard Medical School, Boston, MA, United States.

B019 **NFAT5 regulates KRAS target therapy resistance in pancreatic cancer**. Pingping Hou. Rutgers New Jersey Medical School, Newark, NJ, United States.

B020 **TRIM7 Inhibition Blocks RTK/RAS Pathway-Driven Tumor Proliferation Independent of Mutation and in the Setting of KRASi Resistance**. George Fromm. Kayak Therapeutics, Inc., Durham, NC, United States.

B021 **Genome-wide CRISPR Screen Identifies Menin as a Mediator of Encorafenib Plus Cetuximab Resistance in BRAF V600E -mutant Colorectal Cancer**. Akash Srivaths. Olivia Newton-John Cancer Research Institute, Melbourne, Australia.

B023 **Identification of TME-dependent resistance and emergence of persister cells to KRAS inhibition**. Niloofar Khairkhah. University of Michigan, Ann Arbor, MI, United States.

B024 **KRAS inhibition is an effective therapy for appendiceal adenocarcinoma: Single cell profiling identifies tumor intrinsic and microenvironmental mechanisms unique to appendix cancer**. John Paul Shen. Univ of Texas MD Anderson, Houston, TX, United States.

B025 **Potential limitation of oncogenic KRAS-targeted therapy in lung cancer due to stromal remodeling**. Brock Humphries. University of Michigan, Ann Arbor, MI, United States.

B026 **RAF1 gene amplification drives RAS inhibitor resistance via nuclear translocation and interactions with PLK1 and Aurora A kinases**. Hitendra Solanki. H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States.

B027 **Functional genomics studies identify determinants of response vs. resistance to pharmacological inhibitors of RAS in multiple myeloma**. Constantine Mitsiades. Dana-Farber Cancer Institute, Boston, MA, United States.

B028 **Adaptive Signaling Rewiring Enables Rapid, Sequential Resistance to KRAS and Pan-RAS Inhibitors**. Ines Pulido. University of Illinois Chicago, Chicago, United States.

B029 **Immune checkpoint-mediated resistance to KRAS G12D inhibition**. Niloofar Khairkhah. University of Michigan, Ann Arbor, MI, United States.

B030 **A window trial in metastatic pancreatic ductal adenocarcinoma reveals resistance mechanisms to targeting the KRAS-MEK pathway**. Motoyuki Tsuda. Oregon Health and Science University, Portland, OR, United States.

B031 **A high-throughput combination screen identifies NT-1 as a superior compound to overcome KRAS G12D inhibitor resistance**. Natalie Thielen. Albert Einstein College of Medicine, Bronx, NY, United States.

B033 **Resistance to the pan-RAS(ON) tri-complex inhibitor daraxonrasib is overcome by direct multi-KRAS inhibitors, QTX3034 and QTX3544**. Jillian Silva. Quanta Therapeutics, South San Francisco, CA, United States.

B034 **Genetic and non-genetic mechanisms of resistance to KRAS inhibition in CRC**. Lukas Dow. Weill Cornell Medicine, New York, NY, United States.

B035 **Investigating adaptive responses in KRAS/LKB1 co-mutant tumors**. Mikoto Kobayashi. University of Michigan, Ann Arbor, MI, United States.

B036 **FYN antagonizes response to RAS inhibition in pancreatic ductal adenocarcinoma**. Hsiu-Chi Ting. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, United States.

B037 **Comparison of RAS G12C(ON) and KRAS G12C(OFF) inhibitor activity in parental or KRAS G12C-amplified tumors via mathematical modeling**. Muhammad Ali Al-Radhawi. Revolution Medicines, Redwood City, CA, United States.

B038 **Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer**. Yijun Gao. Sun Yat-sen University Cancer Center, Guangzhou, Taiwan (Greater China).

B040 **Understanding and Overcoming RAS-pathway Mediated Therapeutic Resistance and Disease Progression in Myeloproliferative Neoplasms**. Subyeta Chowdhury. Memorial Sloan Kettering Cancer Center, New York, NY, United States.



B041 **TIMP1-Mediated regulation of angiogenesis differs between KRAS-Dependent and KRAS-Independent cells in NSCLC**. Ilamathi M-Thirusenthilarasan. Penn State College of Medicine, Hershey, PA, United States.

B042 **Therapeutic options for cancers with oncogenic Ras mutations**. Andrew Wolfe. Hunter College, New York, NY, United States.

B043 **Multi-Omic mapping reveals stress-MAPK-dependent mechanisms of resistance to KRAS G12C inhibitors in colorectal cancer**. Kasturi Nayak. Quantitative Biosciences Institute and Department of Medicine, University of California San Francisco, San Francisco, CA, United States.

B012 **A PP2A molecular glue overcomes RAS/MAPK inhibitor resistance in KRAS-mutant non–small cell lung cancer**. Goutham Narla. The University of Michigan, Ann Arbor, MI, United States.

B044 **Silent KRAS mutations confer altered sensitivity to targeted KRAS inhibition**. Andrew Waters. University of Cincinnati, Cincinnati, OH, United States.

B046 **Pan-RAS Inhibition as a novel therapeutic strategy for RAS-driven rhabdomyosarcoma**. Patience Odeniyide. The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, United States.

B047 **Pre-treatment with azacytidine sensitizes RAS-mutated secondary AML to the pan-RAS inhibitor RMC-7977**. Tessa Seale. Johns Hopkins University School of Medicine, Baltimore, MD, United States.

B048 **De novo design of Ras isoform selective binders**. Jason Zhang. UCLA, Los Angeles, CA, United States.

B049 **Overcoming treatment adaptation to RAS(ON) inhibition in NRAS/HRAS mutant pediatric tumors**. Anand Patel. St. Jude Children's Research Hospital, Memphis, TN, United Arab Emirates.

B050 **Identifying and characterizing the role of the adapter protein, LNK in NRAS mutant melanoma**. Meghan Vrkoc. McGill University, Montreal, QC, Canada.

B051 **Targeting RAS to stimulate pyroptosis and antitumor immunity in acral melanoma**. Geethanjali Annamalai. Thomas Jefferson University, Philadelphia, PA, United States.